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Abstract
Sarcomatoid renal cell carcinoma (sRCC) is a highly aggressive form of dedifferentiated renal cell carcinoma. We report a 62-year-
old man who presented with respiratory symptoms and a lung mass on chest computed tomography (CT). The patient underwent 
positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (18F-FDG) and was found to have 
extensive metastatic disease. Based on the history and imaging findings, there were possible primary malignancies, including 
bronchogenic carcinoma, melanoma, or an aggressive lymphoma. An excisional biopsy surprisingly revealed a high-grade sar-
comatoid carcinoma with no evidence of differentiation, and immunohistochemical (IHC) studies showed that the tumor cells 
were positive for markers of genitourinary origin (PAX-8 and vimentin). The histologic and IHC results, along with multiple 
FDG-avid exophytic lesions in both kidneys, were considered diagnostic of sRCC. Here we have highlighted the potential role of 
18F-FDG-PET-CT in patients with sRCC, discussed the diagnostic challenges, and presented a brief  review.
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Introduction
The term “sarcomatoid renal cell carcinoma” (sRCC) was 
first used by Farrow et al. in 1968 to describe tumors that had 
progressed or transformed to a high grade, pleomorphic often 
spindle cell malignancy with a resemblance in most cases 
to pleomorphic undifferentiated sarcoma (1). Sarcomatoid 
dedifferentiation of a renal cell carcinoma (RCC) can occur 
with all histological subtypes. Since clear cell RCC is the most 
common subtype, approximately 80–90% of sRCCs are as-
sociated with this subtype (2). Sarcomatoid progression may 
occur in 10–20% of RCCs in patients with advanced disease 
and it is thought to be a major factor in RCC mortality (3, 4).
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Positron emission tomography/computed tomography 
(PET/CT) with 18F-fluorodeoxyglucose (18F-FDG) has been 
shown to be a valuable tool in the detection of recurrent and 
metastatic disease in patients with typical RCC. However, 
characterization of the primary tumor can be difficult because 
of physiological excretion of FDG by the kidneys. Further-
more, well-differentiated RCCs often have only mildly in-
creased FDG uptake that is similar to that of normal renal 
parenchyma (5–8). Since sRCC is more aggressive and has a 
higher metastatic potential than conventional RCC, 18F- FDG-
PET/CT may play an important role in the management and 
follow-up of these cases. Review of the literature yielded only 
three previously reported cases of metastatic sRCC evalu-
ated by 18F-FDG –PET/CT (9–11). In this report, we de-
scribe a case of sRCC in a patient in whom the initial staging 
18F-FDG-PET/CT revealed widespread metastatic disease.
Case Report
A 62-year-old man presented to his primary care physician 
with a dry, nonproductive cough with no hemoptysis for 
6 weeks. He was initially diagnosed with atypical pneumonia 
and started on antibiotics, but his symptoms did not improve. 
The patient then presented to the emergency department at 
the Washington University Medical Center with worsening 
of cough, dyspnea on exertion, left rib pain, weight loss, 
and fatigue. A chest radiograph revealed a 9-cm middle me-
diastinal mass. Further workup with contrast-enhanced CT 
disclosed multifocal lesions, including an enhancing right 
lower lobe mass invading into the mediastinum, as well as 
multiple enhancing soft tissue nodules within the perito-
neum, both adrenal glands and the pancreas. These findings 
were initially thought to represent a metastatic primary bron-
chogenic carcinoma.
The patient was referred for 18F-FDG-PET/CT the next 
day to further evaluate the disease extent. A whole-body PET/
CT was performed 60 min after the intravenous injection of 
629 MBq (17 mCi) 18F-FDG. The study showed multiple hy-
permetabolic foci throughout the body (Figure 1). There was 
a large soft tissue mass in the right lower lobe with increased 
18F-FDG uptake; the maximum standardized uptake value 
(SUV
max
) of this lesion was 38.0. Also, there were multiple 
Figure 1. Maximum intensity projection (MIP) images in anterior and posterior views of the 18F-FDG PET/CT images showing 
multiple hypermetabolic foci of increased FDG uptake throughout the body, most likely representing widespread metastatic 
disease.
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hypermetabolic nodules in the thyroid, gastric mucosa, pan-
creas, and both the adrenals. Both kidneys contained exo-
phytic lesions with increased 18F-FDG uptake (Figure  2). 
A circumferential soft tissue mass in the esophagus was 
hypermetabolic as well. Additional FDG-avid nodules and 
masses were also found in the peritoneum and omentum; the 
largest of these had a SUV
max
 of 68.0. Intense FDG uptake 
was observed in multiple subcutaneous and intramuscular 
nodules throughout the body, some of which were thought 
to represent lymph nodes. Brain magnetic resonance imaging 
was performed on the same day, which revealed five meta-
static lesions measuring up to 1.5 cm in the left frontal lobe, 
anterior right parietal lobe, and right temporal lobe. At this 
point, there were multiple candidate lesions for the primary 
malignancy, such as lung, esophagus, melanoma, or an ag-
gressive lymphoma.
An excisional biopsy of  the right cervical lymph node 
was performed based on the 18F-FDG PET/CT findings. A 
portion of  this tissue was sent for flow cytometry prior to 
microscopic analysis, to exclude a hematologic malignancy, 
and a standard lymphoma analysis was performed. Front 
and side scatter size gating found 0% of  the cells to be blasts, 
and only 2% of  the cells were identified as lymphocytes. Of 
these gated cells (lymphocytes), 0% were positive for the pan 
B-cell markers CD-19 and CD-20. Furthermore, no clon-
ality assessed by kappa/lambda staining was identified. Of 
the gated cells, 95% were positive for the pan T-cell marker 
CD-3. This was consistent with entire replacement of  the 
lymph node with tumor. The rare hematologic cells that 
were identified represented a small population of  tumor in-
filtrating T-cells, a common phenomenon. The remaining 
portion was sent for histologic analysis, and was found to 
be a high-grade sarcomatoid carcinoma with no evidence of 
differentiation (Figure 3A). Immunostaining demonstrated 
the tumor cells were negative for both cytokeratin 7 and 20, 
and positive for vimentin and PAX-8, suggesting that the 
cancer in the sampled cervical lymph node was most likely 
a metastasis from a primary cancer of  genitourinary origin. 
After correlation with the imaging studies, which identified 
bilateral, FDG-avid, exophytic lesions in the kidneys, a final 
diagnosis of  sarcomatoid carcinoma of  renal origin was 
rendered (Figure 3B). A detailed listing of  the reagents used 
for histopathologic analysis of  the tumor tissue is available 
on the journal’s website at: https://jkcvhl.com/index.php/
jkcvhl/rt/suppFiles/99/0.
The patient underwent stereotactic radiosurgery to five 
brain lesions, and chemotherapy with carboplatin and pacl-
itaxel protein-bound particles (ABRAXANE®) was imme-
diately initiated. He did not tolerate the treatment well and 
CT showed progression of the disease. Second-line treatment 
with pembrolizumab was started. Unfortunately, a few days 
after the first cycle, the patient died.
Discussion
sRCC is a highly malignant tumor that contains features 
similar to sarcomas, with spindle-like cells, high cellularity, 
and cellular atypia (4). Patients with sRCC have the worst 
prognosis among all patients with RCC, even among those 
with initially localized disease, with a median overall survival 
of 3 to 10 months (12). Preclinical and clinical data suggest 
susceptibility to cytotoxic agents and vascular endothelial 
growth factor-targeted therapies, but with poor response 
rates (13). A study by Joseph et al. has shown that sRCCs 
express PD-1/PD-L1 at a higher percentage than RCC with-
out sarcomatoid differentiation, making sRCC patients good 
Figure 2. Axial 18F-FDG PET/CT fusion images. Foci of markedly increased 18F-FDG uptake are shown in the peritoneal cavity, 
and in exophytic lesions in the kidneys bilaterally.
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candidates for treatment with anti–PD-1/PD-L1 agents (14). 
Phase 1 data with atezolizumab, a PD-L1 antibody, showed 
early evidence of antitumor activity in sRCC, with an 
objective response rate of 22% (15). However, further stud-
ies are needed to establish the optimal combination of cyto-
toxic chemotherapy, targeted agents, and immunotherapy to 
improve outcomes in these patients.
The role of 18F-FDG-PET/CT for primary RCC is still 
controversial because of the renal excretion of 18F-FDG and 
the relatively low 18F-FDG uptake of many tumors (8). How-
ever, 18F-FDG PET/CT has shown to be effective for detec-
tion of suspected recurrent RCC (5, 8).
The use of 18F-FDG-PET/CT in the evaluation of sRCC 
has only been described in three prior case reports. Tham-
bugala et al. described metastatic dissemination of a sRCC 
after nephrectomy (9). Conventional imaging of this patient 
with recurrent sRCC showed metastatic spread to para-aortic 
nodes, but 18F-FDG-PET/CT identified extensive local 
recurrence that involved the left renal bed and retroperito-
neal soft tissues, as well as abdominal and mediastinal nodal 
and  osseous metastases. Hyodo et al. reported a patient 
with sRCC in whom post-nephrectomy 18F-FDG-PET/CT 
demonstrated disseminated metastatic lesions in mediastinal 
lymph nodes, lungs, and the right infraspinatus muscle with 
intense 18F-FDG uptake (10).
Recently, Nadebaum et al. also reported a patient with 
recurrent sRCC, who had two subpopulations of disease with 
different imaging phenotypes on PET/CT with 18F-FDG 
and with the prostate-specific membrane antigen (PSMA) 
ligand, 68Ga-PSMA-HBED-CC. Based on the findings in 
this patient, they suggested that the sarcomatoid dedifferen-
tiation is associated with a loss of PSMA expression and a 
concomitant upregulation of GLUT-1 transporter expres-
sion, increasing 18F-FDG avidity (11).
Figure 3. A diagnostic challenge. (A) On hematoxylin–eosin staining, this excisional biopsy demonstrates a lymph node that has 
been entirely replaced by a high-grade, eosinophilic, homogeneously sarcomatoid malignancy with no evidence of differenti-
ation. There is a high degree of both cellular atypia, ranging from spindled cells to fried egg cells, and nuclear atypia, featur-
ing vesicular chromatin, irregular nuclear borders, and prominent nucleoli. A portion of this tissue was sent for flow cytometry 
prior to microscopic analysis, which excluded a hematologic malignancy, as no significant lymphoid population was identified. 
(B) Immunostaining to identify the tissue of origin for this malignancy demonstrated tumor cell nonreactivity for cytokeratins 
7 and 20, with reactivity for vimentin and PAX8. These immunohistochemical and morphological findings are most consistent with 
a high-grade sarcomatoid carcinoma of renal origin. (C) Interrogation of prognostic/predictive markers by immunohistochemistry 
demonstrated high PD-L1 expression levels and was negative for BRAF V600E hotspot mutation. Fluorescence In Situ Hybridiza-
tion studies with break-apart probes were negative for rearrangements in ALK and ROS1, suggesting that this patient might benefit 
from treatment with pembrolizumab and would be less likely to benefit from treatment with crizotinib and dabrafenib.
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In all three prior reports, 18F-FDG-PET/CT was per-
formed after nephrectomy to evaluate recurrent/metastatic 
disease and, therefore, evaluation of primary sRCC was not 
possible. Our patient had metastatic disease of unknown pri-
mary origin at the time of the PET/CT study. After the final 
diagnosis of sRCC, the renal lesions were recognized retro-
spectively as multiple hypermetabolic exophytic lesions bilat-
erally, with high 18F-FDG uptake relative to that of normal 
renal parenchyma. The findings in our patient also demon-
strate the high 18F-FDG avidity of sRCC metastatic lesions, 
consistent with the findings of the three previously reported 
cases.
Histologically, this was a very high-grade lesion. The 
primitive phenotype of  the cancer cells posed a diag-
nostic challenge in the setting of  widespread disease 
and significant tumor burden in multiple organs, any of 
which could have been the primary tumor site. While the 
initial panel of  immunostains suggested the primary 
lesion to be of  urogenital origin, it also revealed a signifi-
cant and unanticipated result, as portions of  the tumor 
demonstrated positivity for SOX10, which is expressed 
predominantly in melanocytes, Schwann cells, and breast 
myoepithelial cells (16). Clinically, it is considered to be 
a relatively specific marker of  melanomas, but it is also 
known to be positive in some malignant peripheral nerve 
sheath tumors as well as in some basal-like, triple-negative 
breast cancers, especially those with a metaplastic carci-
noma component (17). Additional assessment of  this lesion 
by MiTF and tyrosinase staining, both of  which were nega-
tive, further supported that this tumor was not a melanoma. 
Rather, the tumor was most likely an sRCC aberrantly ex-
pressing primitive transcription factors known developmen-
tally to be crucial in the specification of  neural crest cells 
(16). To our knowledge, this is the first reported case of  a 
SOX10-positive sRCC.
Given the unique cellular and molecular phenotypes ob-
served in the excisional biopsy, it would have been interest-
ing to sample additional lesions from this patient in order to 
assess whether or not a gradient of dedifferentiation and/or 
epithelial to mesenchymal transition exists between the pri-
mary tumors and the various deposits of metastatic disease, 
which demonstrated significant variation in the SUV
max
 on 
18F-FDG-PET/CT.
Conclusion
sRCC is a highly aggressive malignancy reported in some 
instances to overexpress GLUT-1 transporters, potentially 
resulting in high 18F-FDG avidity. Although the impact of 
18F-FDG-PET/CT in sRCC has only been reported in three 
cases of recurrent disease, and must be further evaluated, the 
findings in our patient suggest that 18F-FDG-PET/CT is also 
potentially valuable for the evaluation of primary sRCC and 
initial staging for detection of metastatic lesions.
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